# Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT

> **NCT01772953** · PHASE2 · COMPLETED · sponsor: **Center for International Blood and Marrow Transplant Research** · enrollment: 40 (actual)

## Conditions studied

- Acute Myeloid Leukemia (AML)
- Myelodysplastic Syndrome (MDS)

## Interventions

- **DRUG:** Treosulfan

## Key facts

- **NCT ID:** NCT01772953
- **Lead sponsor:** Center for International Blood and Marrow Transplant Research
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09
- **Primary completion:** 2015-08
- **Final completion:** 2015-08
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2016-10-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01772953

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01772953, "Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01772953. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*